Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan. [electronic resource]
Producer: 20211004Description: 601-610 p. digitalISSN:- 1744-8352
- B7-H1 Antigen -- antagonists & inhibitors
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- DNA Mutational Analysis -- economics
- Databases, Nucleic Acid
- Device Approval -- legislation & jurisprudence
- Direct-To-Consumer Screening and Testing -- economics
- Drug Resistance, Microbial -- genetics
- Equipment and Supplies -- classification
- Genetic Diseases, Inborn -- drug therapy
- Government Agencies -- organization & administration
- Health Services Needs and Demand
- High-Throughput Nucleotide Sequencing -- economics
- Humans
- Immune Checkpoint Inhibitors -- pharmacology
- Japan
- Lung Neoplasms -- drug therapy
- Medical Device Legislation
- Molecular Diagnostic Techniques -- economics
- Molecular Targeted Therapy
- Mutation
- National Health Programs
- Neoplasm Proteins -- antagonists & inhibitors
- Neoplasms -- drug therapy
- Precision Medicine -- methods
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.